

Name : Mr. NIKHIL RANA

Lab No. 148525254

A/c Status

Age: 27 Years

Ref By: Dr. SELF

Gender:

Male

Collected Received : 6/11/2019 9:11:00AM

: 6/11/2019 9:36:29AM : 6/11/2019 3:25:56PM Reported

Final Report Status

Test Name	Results	Units	Bio. Ref. Interval
SWASTHFIT SUPER 2 PACKAGE			
LIVER & KIDNEY PANEL, SERUM (Spectrophotometry, Indirect ISE)			
Bilirubin Total	0.52	mg/dL	0.30 - 1.20
Bilirubin Direct	0.12	mg/dL	<0.20
Bilirubin Indirect	0.40	mg/dL	<1.10
AST (SGOT)	38	U/L	<50
ALT (SGPT)	64	U/L	<50
GGTP	22	U/L	<55
Alkaline Phosphatase (ALP)	110	U/L	30 - 120
Total Protein	7.91	g/dL	6.40 - 8.30
Albumin	4.78	g/dL	3.50 - 5.20
A : G Ratio	1.53		0.90 - 2.00
Urea	23.00	mg/dL	17.00 - 43.00



Page 1 of 10



Name : Mr. NIKHIL RANA	Collected : 6/11/2019 9:11:00AM
Lab No. : 148525254 Age: 27 Years Gender: Male	Received : 6/11/2019 9:36:29AM Reported : 6/11/2019 3:25:56PM
A/c Status : P Ref By : Dr. SELF	Report Status : Final

Test Name Creatinine	Results 0.71	<b>Units</b> mg/dL	<b>Bio. Ref. Interval</b> 0.67 - 1.17
Uric Acid	6.70	mg/dL	3.50 - 7.20
Calcium, Total	9.73	mg/dL	8.80 - 10.60
Phosphorus	3.43	mg/dL	2.40 - 4.40
Sodium	136.00	mEq/L	136.00 - 146.00
Potassium	4.53	mEq/L	3.50 - 5.10
Chloride	102.00	mEq/L	101.00 - 109.00





Name : Mr. NIKHIL RANA

Lab No.

A/c Status

: 148525254 Age: 27 Years

Ref By: Dr. SELF

Gender: Male

Collected Received : 6/11/2019 9:11:00AM

Reported

: 6/11/2019 9:36:29AM : 6/11/2019 3:25:56PM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interva
COMPLETE BLOOD COUNT;CBC (Electrical Impedence & Flow)			
Hemoglobin	15.00	g/dL	13.00 - 17.00
Packed Cell Volume (PCV)	45.70	%	40.00 - 50.00
RBC Count	5.13	mill/mm3	4.50 - 5.50
MCV	89.10	fL	80.00 - 100.00
MCH	29.20	pg	27.00 - 32.00
MCHC	32.80	g/dL	32.00 - 35.00
Red Cell Distribution Width (RDW)	13.70	%	11.50 - 14.50
Total Leukocyte Count (TLC)	8.55	thou/mm3	4.00 - 10.00
Differential Leucocyte Count (DLC)			
Segmented Neutrophils	69.40	%	40.00 - 80.00
Lymphocytes	23.40	%	20.00 - 40.00
Monocytes	6.00	%	2.00 - 10.00
Eosinophils	1.10	%	1.00 - 6.00
Basophils	0.10	%	<2.00
Absolute Leucocyte Count			
Neutrophils	5.93	thou/mm3	2.00 - 7.00
Lymphocytes	2.00	thou/mm3	1.00 - 3.00
Monocytes	0.51	thou/mm3	0.20 - 1.00
Eosinophils	0.09	thou/mm3	0.02 - 0.50
Basophils	0.01	thou/mm3	0.01 - 0.10
Platelet Count	165.0	thou/mm3	150.00 - 450.00



Page 3 of 10



Name : Mr. NIKHIL RANA

Lab No. : 148525254

Age: 27 Years

Ref By: Dr. SELF

Gender: Male

Collected Received Reported : 6/11/2019 9:11:00AM : 6/11/2019 9:36:29AM

: 6/11/2019 3:25:56PM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
Mean Platelet Volume (MPV)	13.90	fL	6.50 - 12.00

#### Note

A/c Status

- As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood
- 2. Test conducted on EDTA whole blood





 Name
 Mr. NIKHIL RANA
 Collected
 : 6/11/2019
 9:11:00AM

 Lab No.
 : 148525254
 Age: 27 Years
 Gender: Male
 Received Reported
 : 6/11/2019
 9:36:29AM

A/c Status : P Ref By : Dr. SELF Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOC (HPLC)	OD		
HbA1c	5.8	%	
Estimated average glucose (eAG)	120	mg/dL	

#### Interpretation


As per American Diabetes Association (ADA)		
Reference Group	HbA1c in %	
Non diabetic adults >=18 years	4.0 - 5.6	
At risk (Prediabetes)	5.7 - 6.4	
Diagnosing Diabetes	>= 6.5	
Therapeutic goals for glycemic   control	. Goal of therapy: < 7.0     . Action suggested: > 8.0	

# Note

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who
  is recently under good control may still have a high concentration of HbA1c. Converse is true for a
  diabetic previously under good control but now poorly controlled
- Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life
  expectancy and no significant cardiovascular disease. In patients with significant complications of
  diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not
  be appropriate</li>
- 3. Any condition that shortens erythrocyte survival such as sickle cell disease, pregnancy (second and third trimesters), hemodialysis, recent blood loss or transfusion, or erythropoietin will falsely lower HbA1c results regardless of the assay method
- 4. In patients with HbA1c level between 7-8%, Glycemark (1,5 Anhydroglucitol) test may be done to identify those with more frequent and extreme hyperglycemic excursions



Page 5 of 10





Name : Mr. NIKHIL RANA

Lab No.

A/c Status

: 148525254 Age: 27

Age: 27 Years

Ref By: Dr. SELF

Gender: Male

Collected Received : 6/11/2019 9:11:00AM

Received : 6/11/2019 9:36:29AM Reported : 6/11/2019 3:25:56PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations. This single test can be used both for diagnosing & monitoring diabetes. ADA recommends measurement of HbA1c 3-4 times per year in Type 1 diabetes and poorly controlled Type 2 diabetes patients. In well controlled Type 2 diabetes patients, the test can be performed twice a year.





6/11/2019 9:11:00AM Name : Mr. NIKHIL RANA Collected 6/11/2019 9:36:29AM Received 148525254 Lab No. Age: 27 Years Gender: Male Reported 6/11/2019 3:25:56PM A/c Status Ref By: Dr. SELF **Report Status** 

Test Name	Results	Units	Bio. Ref. Interval
THYROID PROFILE,TOTAL, SERUM (Chemiluminescent Immunoassay)			
T3, Total	1.02	ng/mL	0.60 - 1.81
T4, Total	6.90	ug/dL	5.01 - 12.45
тѕн	2.52	uIU/mL	0.35 - 5.50

### Note

- 1. TSH levels are subject to circadian variation, reaching peak levels between 2 4.a.m. and at a minimum between 6-10 pm. The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 2. Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
- 3. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

# **Clinical Use**

- · Primary Hypothyroidism
- Hyperthyroidism
- Hypothalamic Pituitary hypothyroidism
- Inappropriate TSH secretion
- Nonthyroidal illness
- Autoimmune thyroid disease
- · Pregnancy associated thyroid disorders
- · Thyroid dysfunction in infancy and early childhood





Name : Mr. NIKHIL RANA

Lab No. : 148525254

A/c Status

Age: 27 Years

Ref By: Dr. SELF

Male

Gender:

Received Reported : 6/11/2019 9:11:00AM

: 6/11/2019 9:36:29AM : 6/11/2019 3:25:56PM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
LIPID PROFILE, SCREEN (Enzymatic Spectrophotometry)			
Cholesterol, Total	177.00	mg/dL	<200.00
Triglycerides	83.00	mg/dL	<150.00
HDL Cholesterol	48.00	mg/dL	>40.00
LDL Cholesterol, Calculated	112.40	mg/dL	<100.00
VLDL Cholesterol,Calculated	16.60	mg/dL	<30.00
Non-HDL Cholesterol	129	mg/dL	<130

# Interpretation

REMARKS	TOTAL CHOLESTEROL   in mg/dL	TRIGLYCERIDE   in mg/dL	LDL CHOLESTEROL   in mg/dL	NON HDL CHOLESTEROL     in mg/dL
Optimal	<200	<150	<100	<130
Above Optimal			100-129	130 - 159
Borderline High	200-239	150-199	130-159	160 - 189
High	>=240	200-499	160-189	190 - 219
Very High		>=500	>=190	>=220

### Note

- 1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
- 2. NLA-2014 recommends a complete lipoprotein profile as the initial test for evaluating cholesterol.
- Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL. Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL
- 4. NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogeniclipoproteins such as LDL,



Page 8 of 10



148525254

Name : Mr. NIKHIL RANA

Lab No.

A/c Status

lake Dr. Lat. Pastilake Dr. Lat. Pastilake ?

Age: 27 Years

Ref By: Dr. SELF

Gender:

Male Recei

: 6/11/2019 9:11:00AM

Received : Reported :

Collected

: 6/11/2019 9:36:29AM : 6/11/2019 3:25:56PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval

VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

- 5. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved
- 6. Additional testing for Apolipoprotein B, hsCRP,Lp(a ) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

# Treatment Goals as per Lipid Association of India 2016


RISK   CATEGORY	TREATMENT GOAL		CONSIDER THERAPY	
CATEGORY	LDL CHOLESTEROL (LDL-C)(mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)	LDL CHOLESTEROL   (LDL-C)(mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)
Very   High	<50 	<80	>=50	>=80
High	<70	<100	>=70	>=100
Moderate	<100	<130	>=100	>=130
Low	<100	<130	>=130*	>=160*

<sup>\*</sup>In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months

Dr Parul Joshi MD, Pathology Chief of Laboratory Dr Lal PathLabs Ltd

-----End of report -----







Mr. NIKHIL RANA

Lab No.

A/c Status

148525254 Age: 27 Years

Ref By: Dr. SELF

Collected

: 6/11/2019 9:11:00AM

Received Reported

: 6/11/2019 9:36:29AM : 6/11/2019 3:25:56PM

Report Status

Final

**Test Name** Results Units Bio. Ref. Interval

Gender:

#### **IMPORTANT INSTRUCTIONS**

Male

\*Test results released pertain to the specimen submitted.\*All test results are dependent on the quality of the sample received by the Laboratory \*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .\*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.\*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.\*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.\*Test results may show interlaboratory variations.\*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).\*Test results are not valid for medico legal purposes. \*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

(#) Sample drawn from outside source.

